IOCB is 50% funded by $90 million/year in royalties from 15 innovative drugs that it has licensed, including : Antivirotics: Duviragel™, cidofovir (Vistide™), adefovir (Hepsera™), tenofovir (Viread™, Truvada™, Atripla™, Striblid™, Complera™); Peptides: Oxytocin™, Adiuretin™, Terlipressin™; Natural Substances: Dermazulen, Lafarex®.” (IOCB = Institute of Organic Chemistry and Biochemistry).
https://lnkd.in/d85eSEg
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022